Decitabine

For research use only. Not for use in humans.

目录号:S1200 别名: Deoxycytidine

Decitabine Chemical Structure

Molecular Weight(MW): 228.21

Decitabine是DNA甲基转移酶抑制剂,整合进入DNA、导致DNA低甲基化,并使DNA复制停滞在intra-S-phase。Decitabine被用于治疗骨髓增生异常综合征(MDS)。

规格 价格 库存 购买数量  
10mM (1mL in DMSO) RMB 1269.11 现货
RMB 732.42 现货
RMB 1419.77 现货
RMB 2621.82 现货
RMB 4679.47 现货
有超大折扣

今日订购,明日送达,全国免运费!

全国免费电话:400-668-6834   |   Email:info@selleck.cn

客户使用Selleck生产的Decitabine发表文献58篇:

产品安全说明书

DNA Methyltransferase抑制剂选择性比较

生物活性

产品描述 Decitabine是DNA甲基转移酶抑制剂,整合进入DNA、导致DNA低甲基化,并使DNA复制停滞在intra-S-phase。Decitabine被用于治疗骨髓增生异常综合征(MDS)。
特性 Decitabine 是DNA甲基化的有效抑制剂。
靶点
DNA methylation [1]
(HL-60, KG1a cells)
体外研究

Decitabine 有效抑制DNA 合成,这种作用存在剂量依赖性,作用于HL-60和 KG1a 白血病细胞时,IC50分别为 100 ng/mL 和1 ng/mL。Decitabine 抑制细胞生长,这种作用存在剂量和时间依赖性,处理HL-60和KG1a白血病细胞72小时和96小时,IC50分别约为100 ng/mL 和 10 ng/mL。[1] 最新研究显示Decitabine作用于间变性大细胞淋巴瘤(ALCL),具有抗增殖和促凋亡活性,且抑制KARPAS-299细胞中[3H]胸甘的摄取,EC50 为0.49 μM。[2]

Cell Data
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
Eca109 MYnGeY5kfGmxbjDBd5NigQ>? NHnTWWgxNjYEoN88US=> MmrsNlQhcA>? NHvZcmJ4[XSnch?= MnTCcY9lfWyjdHXzJJRp\SCpZX7lJIV5eHKnc4Ppc44hd2ZiTVHHSU1CKG2nbXLldpM> Ml;xNlUyOjNyOEK=
Eca109 MXLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M4H3OFAvPS9{LkWvOUDPxE1? NF7zdY8zPC92OD:3NkBp MlT4e4F1\XJ? NWe2OZpkcW6qaXLpeJMh[2WubDDndo94fGhiaX6gZo91cCCmb4PlMUBidmRidHnt[U0h\GWyZX7k[Y51KG2jbn7ldi=> NIX3RogzPTF{M{C4Ni=>
Eca109 M4XwR2Z2dmO2aX;uJGF{e2G7 NI[xfWgxNjYEoN88US=> M2jRR|YwOTJxMkSgbC=> NWrwXotNf2G2ZYK= NVm1WXNScW6qaXLpeJMh[2WubDDtbYdz[XSrb39CpC=> NXHtUGNYOjVzMkOwPFI>
Eca109 NH20SWJHfW6ldHnvckBCe3OjeR?= M2fKc|AvPcLizszN NFXROVUzPCCq MX33ZZRmeg>? MXTpcohq[mm2czDj[YxtKGmwdnHzbY9v MoDONlUyOjNyOEK=
Eca109 MX;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Mn7xNE42yqEQvF2= MXGyOEBp M4TxVpdifGW{ MoGxbY5lfWOnczDHNk9OKGG{cnXzeEBqdiC2aHWgZ4VtdCCleXPs[S=> NUXpOFBSOjVzMkOwPFI>
Eca109 MXzGeY5kfGmxbjDBd5NigQ>? M2TnfFAvPS9zIN88US=> NIfzfpQzPCCq MoPUe4F1\XJ? MVjk[YNz\WG|ZYOg[ZhxemW|c3nvckBw\iCQRj5OvmIzKGGwZDDNUXAz M4ntOlI2OTJ|MEiy
SW1116  M1nUZWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3HIb|AvPS9zL{KvOUDPxE1? NGLRZm81QCCq M4TUSGROW09? MVzlcohidmOnczD0bIUhT2WoaYTpcoljKGmwZIXj[YQh[2WubDDpcohq[mm2aX;u NWjvUlhJOjR6N{SyPFY>
LOVO NVGyWpFDT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MUOwMlUwOS9{L{Wg{txO MkLOOFghcA>? NWnYephPTE2VTx?= NGnrPYRmdmijbnPld{B1cGViR3XmbZRqdmmkIHnu[JVk\WRiY3XscEBqdmirYnn0bY9v MXKyOFg4PDJ6Nh?=
SW1116  NYrUXXhOTnWwY4Tpc44hSXO|YYm= Mn61NVAh|ryP MUm0PEBp NIjRfIdFVVOR MnnsbY5kemWjc3XzJJRp\SCnZn\lZ5RqfmViYYSgbY5pcWKrdHnu[{BCU1RiYX7kJI1VV1Jic3nncoFtcW6pIIDheIh4[Xm|IHPvcYJqdmWmIIfpeIgh\2WoaYTpcolj MX:yOFg4PDJ6Nh?=
LOVO MVjGeY5kfGmxbjDBd5NigQ>? MUSxNEDPxE1? MV20PEBp MVLEUXNQ M3rPWYlv[3KnYYPld{B1cGViZX\m[YN1cX[nIHH0JIlvcGmkaYTpcochSUuWIHHu[EBuXE:UIIPp[45idGmwZzDwZZRpf2G7czDjc41jcW6nZDD3bZRpKGenZnn0bY5q[g>? MVSyOFg4PDJ6Nh?=
SW1116  NEfQO5dCeG:ydH;zbZMhSXO|YYm= NWr5dpB7OTBizszN MWi0PEBp MmSxSG1UVw>? NUnYcpZr\W6qYX7j[ZMhT2WoaYTpcoljNWmwZIXj[YQh[XCxcITvd4l{ NF2yW2ozPDh5NEK4Oi=>
LOVO NEDoXWVCeG:ydH;zbZMhSXO|YYm= NXGyZVhSOTBizszN NFLK[|E1QCCq M{fXdGROW09? NYD0OplU\W6qYX7j[ZMhT2WoaYTpcoljNWmwZIXj[YQh[XCxcITvd4l{ M1iwblI1QDd2Mki2
RPMI-8226 MYLBdI9xfG:|aYOgRZN{[Xl? NI\LZ3gyNzJizszN NEX6VFg1QC95Mj:5OkBp NUK1epU2TE2VTx?= M3fnPIlv\HWlZYOgZ4VtdCCjcH;weI9{cXN? NFO0cHQzPDh|M{GwPC=>
OPM-2  MUXBdI9xfG:|aYOgRZN{[Xl? NXX1Xm1wOS9{IN88US=> NY\C[WVJPzJxOU[vNVIxKGh? NYi1e5NXTE2VTx?= MULpcoR2[2W|IHPlcIwh[XCxcITvd4l{ M3Hod|I1QDN|MUC4
JJN3  M17Hc2Fxd3C2b4Ppd{BCe3OjeR?= NXzU[YJIOC53L{Gg{txO MV6yOE81QCCq M4jXOWROW09? M2nuUIlv\HWlZYOgZ4VtdCCjcH;weI9{cXN? MUSyOFg{OzFyOB?=
NCI-H929  MX;BdI9xfG:|aYOgRZN{[Xl? NF3FWY4yNzJizszN NVLnbnpvPzJxOU[vNVIxKGh? MVLEUXNQ NHzWblVqdmS3Y3XzJINmdGxiYYDvdJRwe2m| MXOyOFg{OzFyOB?=
RPMI-8226 NYryV2EyT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NVf5cFl2OS9{IN88US=> Ml\ZNlQwPDhxN{KgbC=> NGSwSWpFVVOR NIThUo1i\m[nY4TzJINmdGxiY4njcIUheHKxZ4Lld5Nqd25ibnXnZZRqfmWueR?= MoPtNlQ5OzNzMEi=
OPM-2  MXjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MVmxM|Ih|ryP M1i0elI1NzR6L{eyJIg> NF;hPIxFVVOR MWDh[oZm[3S|IHPlcIwh[3mlbHWgdJJw\3Knc4Ppc44hdmWpYYTpeoVtgQ>? NX[1OGhIOjR6M{OxNFg>
JJN3  NEe5cVBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Mo\3NE42NzFizszN NGLsbIkzPC92OD:3NkBp MUTEUXNQ M3TPPIFn\mWldIOgZ4VtdCCleXPs[UBxem:pcnXzd4lwdiCwZXfheIl3\Wy7 NWTOTXI3OjR6M{OxNFg>
NCI-H929  NH2x[mlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NWX2XoR5OS9{IN88US=> M3e4VlI1NzR6L{eyJIg> MoLDSG1UVw>? MlTHZYZn\WO2czDj[YxtKGO7Y3zlJJBzd2e{ZYPzbY9vKG6nZ3H0bZZmdHl? M1zOPVI1QDN|MUC4
HeLa Ml\zT4lv[XOnIFHzd4F6 Mk[xT4k:OTByMPMAl|UxODBizszNJIZweiCqRV7UNS=> M2j6WFI1PzhyMEm4
HeLa NGfhWG9McW6jc3WgRZN{[Xl? NFPGSG9McT13Lk[gxtEhOC53IN88UUBnd3JiaFXOWFI> MYqyOFc5ODB7OB?=
HeLa MoS5T4lv[XOnIFHzd4F6 MV;LbV0zOS54INMxJFMvOCEQvF2g[o9zKGiFTmSx M2DDOVI1PzhyMEm4
HeLa MnLGT4lv[XOnIFHzd4F6 MWfLbV0yPC52INMxJFQvPiEQvF2g[o9zKGiFTmSz NG\ZXJAzPDd6MEC5PC=>
NB4 M3jo[GZ2dmO2aX;uJGF{e2G7 MojINk42NzVxNz61M|ExKM7:TR?= NFXzeYYzPCCq NYG4O2gyTE2VTx?= NVLCfJhDcW6lcnXhd4ViKHSqZTDlfJBz\XO|aX;uJI9nKHC{ZXP1dpNweiCvaWKtNVI2[Q>? MWCyOFQ5PDh5MB?=
CD4+ CD25− T  NUD0VopbTnWwY4Tpc44hSXO|YYm= MU[xM|Uh|ryP NX\YTVFWemWmdXPlV{BodG:kYXygSG5CKG2ndHj5cIF1cW:w M3ezPFI1PDd4M{[w
BV-173 Ml;WRZBweHSxc3nzJGF{e2G7 NUTqWllROC5{NT:wMlUwOC55NT:xJO69VQ>? NWT1VmR{PDhxN{KvPVYhcA>? NUmyc5huyqCSQmO= MYHpcoR2[2W|IHPlcIwh[XCxcITvd4l{KGmwIHLveIgh\G:|ZT2gZY5lKHSrbXWtJIRmeGWwZHXueEBu[W6wZYK= NX\1V3ZPOjR2MkO2NVM>
ML-1 NXvhTIFxSXCxcITvd4l{KEG|c3H5 MWSwMlI2NzBwNT:wMlc2NzFizszN NHHpVpE1QC95Mj:5OkBp NFSwNXbDqFCEUx?= MY\pcoR2[2W|IHPlcIwh[XCxcITvd4l{KGmwIHLveIgh\G:|ZT2gZY5lKHSrbXWtJIRmeGWwZHXueEBu[W6wZYK= NFjJ[XQzPDR{M{[xNy=>
HL-60 M4DpbGFxd3C2b4Ppd{BCe3OjeR?= M3rVfVAvOjVxMD61M|AvPzVxMTFOwG0> MnS1OFgwPzJxOU[gbC=> NF;6VFXDqFCEUx?= MVXpcoR2[2W|IHPlcIwh[XCxcITvd4l{KGmwIHLveIgh\G:|ZT2gZY5lKHSrbXWtJIRmeGWwZHXueEBu[W6wZYK= MVGyOFQzOzZzMx?=
KG-1a MlfiRZBweHSxc3nzJGF{e2G7 M333S|AvOjVxMD61M|AvPzVxMTFOwG0> MUK0PE84Oi97NjDo NHeze27DqFCEUx?= NH:2cJpqdmS3Y3XzJINmdGxiYYDvdJRwe2m|IHnuJIJwfGhiZH;z[U0h[W6mIITpcYUuKGSncHXu[IVvfCCvYX7u[ZI> MYWyOFQzOzZzMx?=
BV-173 M1mxOGZ2dmO2aX;uJGF{e2G7 Mn3HNlUxNzVyMH7N Mo\VOFghcA>? M2L2[uKhWEKV MlXRbY5lfWOnczDk[YxigWWmIHHu[EB{fXO2YXnu[YQhWk:VIHnuZ5Jm[XOn Mo[0NlQ1OjN4MUO=
CEM NITLcIFHfW6ldHnvckBCe3OjeR?= MmrnNlUxNzVyMH7N MVq0PEBp NVfLZWJ2yqCSQmO= M3XITYlv\HWlZYOg[IVt[XmnZDDhcoQhe3W|dHHpcoVlKFKRUzDpcoNz\WG|ZR?= MYCyOFQzOzZzMx?=
HL-60 MlrVSpVv[3Srb36gRZN{[Xl? MkD4NlUxNzVyMH7N M{jDRlQ5KGh? M3vEV:KhWEKV M3XMeolv\HWlZYOg[IVt[XmnZDDhcoQhe3W|dHHpcoVlKFKRUzDpcoNz\WG|ZR?= M32yNFI1PDJ|NkGz
ML-1 MnvjSpVv[3Srb36gRZN{[Xl? MXSyOVAwPTBybl2= NIHwXHM1QCCq Ml:1xsBRSlN? NFSzfWVqdmS3Y3XzJIRmdGG7ZXSgZY5lKHO3c4ThbY5m\CCUT2OgbY5kemWjc3W= M4fNdVI1PDJ|NkGz
DLD-1 MWfGeY5kfGmxbjDBd5NigQ>? MmXlNlUxNzVyMH7N M3\ZTVQ5KGh? Ml76xsBRSlN? NXTu[4dj\G9ibn;0JIlv\HWlZYOg[IVt[XmnZDDhcoQhe3W|dHHpcoVlKFKRUzDpcoNz\WG|ZR?= MXSyOFQzOzZzMx?=
HCT-116 MXvGeY5kfGmxbjDBd5NigQ>? NHTRbm8zPTBxNUCwcm0> MmXiOFghcA>? M{[xRuKhWEKV Ml3M[I8hdm:2IHnu[JVk\XNiZHXsZZlm\CCjbnSgd5V{fGGrbnXkJHJQWyCrbnPy[YF{\Q>? NEPqfIUzPDR{M{[xNy=>
U937-A/E-9/14/18  MnjaRZBweHSxc3nzJGF{e2G7 NYe1VWp7OC5yMT:wMlEwOS9zMDFOwG0> MWC0PEBp MmD4bY5lfWOnczDj[YxtKGGyb4D0c5NqeyCrbjDhJIRwe2VvZHXw[Y5l\W62IH3hco5meg>? NGnNRYozPDNyMES1Oi=>
HT29 NETyNYNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NEKxN3A4OiCq MVnJR|UxRTF2MEFCtVE4QSEQvF2= MmLJNlQyPzJyNkG=
SW48 MknIS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MWO3NkBp MWXJR|UxRTF3LkNCtVYvOiEQvF2= M3P5W|I1OTd{ME[x
HCT116 M1rRNWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NEG0bZk4OiCq M4frb2lEPTB;MT63xtExNjRizszN NXfMT|YzOjRzN{KwOlE>
HepG2 NFPK[29HfW6ldHnvckBCe3OjeR?= M33TO|AvPS9zIN88US=> MV:yOEBp NX;2VWlXTE2VTx?= M4\l[JVxNXKnZ4XsZZRm\CC2aHWgdoVt[XSrdnWgU2NVVjJibWLORUBidmRicILveIVqdiCneIDy[ZN{cW:w NIHoV3QzPDF2Nki3OC=>
LS174T NILycHpHfW6ldHnvckBCe3OjeR?= NUjVcXJ2OC53L{Gg{txO NVTWVmx1OjRiaB?= M1qwfWROW09? Ml24cIVi\CC2bzDhckBqdmO{ZXHz[UBw\iCRQ2TONkBt\X[nbIO= MnLLNlQyPDZ6N{S=
HepG2 NWew[VJ{SXCxcITvd4l{KEG|c3H5 NETiNYgyNzFyL{GwNEDPxE1? NIjW[Iw4KGR? M4XadmROW09? NHrGSFFqdmS3Y3XzJINmdGxiYYDvdJRwe2m|IHnuJIEh\G:|ZT3k[ZBmdmSnboSgcYFvdmW{ M{XzdFI1OTR4OEe0
LS174T MmXxRZBweHSxc3nzJGF{e2G7 M3XUeFEwOTBxMUCwJO69VQ>? MVG3JIQ> MVfEUXNQ MkHxbY5lfWOnczDj[YxtKGGyb4D0c5NqeyCrbjDhJIRwe2VvZHXw[Y5l\W62IH3hco5meg>? NE\EOGwzPDF2Nki3OC=>
QBC-939 NXTPSlR1SXCxcITvd4l{KEG|c3H5 MVuxM|ExNzFyMDFOwG0> NGnCWoM4KGR? M3fQ[GROW09? M2HxXIlv\HWlZYOgZ4VtdCCjcH;weI9{cXNiaX6gZUBld3OnLXTldIVv\GWwdDDtZY5v\XJ? NEiySlkzPDF2Nki3OC=>
U251 M1fQOGFxd3C2b4Ppd{BCe3OjeR?= NELhcZYyNzFyL{GwNEDPxE1? NGL1co04KGR? NWT0TFhWTE2VTx?= MojLbY5lfWOnczDj[YxtKGGyb4D0c5NqeyCrbjDhJIRwe2VvZHXw[Y5l\W62IH3hco5meg>? NYjtSYJCOjRzNE[4O|Q>
HL-60 MmLBS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1L2XFEh|ryP NUWycmtIPDhiaB?= MWfpcoNz\WG|ZYOgS|IueGijc3WgZ4VtdCCocnHjeIlwdg>? MX[yOFAxODN{NB?=
MDA‑MB‑453 NITT[nRHfW6ldHnvckBCe3OjeR?= M17KblAvOi9zIN88US=> MnnyO|IhcA>? NFTq[Itk[XW|ZYOgdoUu\XiycnXzd4lwdiCxZjDjcIF2\GmwwrCxxsA> MV:yN|g1PDJ{OB?=
HCC1569 NVjqTJZmTnWwY4Tpc44hSXO|YYm= MV6wMlIwOSEQvF2= MWC3NkBp NXzsVnlq[2G3c3XzJJJmNWW6cILld5Nqd25ib3[gZ4xifWSrbtMgNeKh MVWyN|g1PDJ{OB?=
BT‑474 NX;SeJY2TnWwY4Tpc44hSXO|YYm= NXflcplIOC5{L{Gg{txO NGi2N5E4OiCq M2qyTYNifXOnczDy[U1mgHC{ZYPzbY9vKG:oIHPsZZVlcW8EoEJCpC=> MlfPNlM5PDR{Mki=
AGS M{HZZWFxd3C2b4Ppd{BCe3OjeR?= NWDzflQ{PS9zMD:yNE82OCEQvF2= NHT6[5I1QMLiaNMg NWG1S3NQTE2VTx?= M2ewUolvcGmkaYTzJJRp\SClZXzsJJZq[WKrbHn0feKh Moe2NlM2QDJ5OES=
A549 NXjHb2NKSXCxcITvd4l{KEG|c3H5 NIrIW3o2NzFyL{KwM|UxKM7:TR?= NI\KcWo1QMLiaNMg NUnnfI17TE2VTx?= MWHpcohq[mm2czD0bIUh[2WubDD2bYFjcWyrdIpCpC=> NYjvVnRKOjN3OEK3PFQ>
AGS  Mn;qS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NHLrbYI2NzFyL{KwM|UxKM7:TR?= Mnu0OFjDqGkEoB?= M2jucmROW09? NEDnUGhqdmS3Y3XzJGczN01icHjhd4Uh[XK{ZYP0xsA> NIHYWJczOzV6Mke4OC=>
Kasumi-1 NUjTe4p{SXCxcITvd4l{KEG|c3H5 MnPKNE42KM7:TR?= M1\kb|Q5yqCqwrC= M3noXoRm[3KnYYPld{B1cGViY3XscEB3cWGkaXzpeJkh[29vdILlZZRm\CC5aYToJHRnNU6SLYPj NV;vXHZDOjN2OUOzOFg>
OCI-AML3 MWfBdI9xfG:|aYOgRZN{[Xl? MX[yMlUh|ryP Mne0OFjDqGkEoB?= M2m4R4Rm[3KnYYPld{B1cGViY3XscEB3cWGkaXzpeJkh[29vdILlZZRm\CC5aYToJHRnNU6SLYPj MnvtNlM1QTN|NEi=
MV4-11 MUPBdI9xfG:|aYOgRZN{[Xl? M2GzV|IvPSEQvF2= MlnBOFjDqGkEoB?= Mlzj[IVkemWjc3XzJJRp\SClZXzsJJZq[WKrbHn0fUBkdy22cnXheIVlKHerdHigWIYuVlBvc3O= NYqzSpZCOjN2OUOzOFg>
NK  M4SzdGN6fG:2b4jpeJkhSXO|YYm= NGLFR2ExNjB{LUKwJO69VQ>? MnHkOUBl MX\k[YNz\WG|ZYOgeIhmKGO7dH;sfZRq[yCjY4Tpeol1gSCxZjDOT{Bk\WyuczDheEBqdnSncn3l[IlifGViY3;uZ4VvfHKjdHnvcpMhemW|dXz0bY5oKGmwIHGgWU1{cGGyZXSg[I9{\eLCk4Lld5BwdnOnIHP1dpZm M1rISVI{OzJ6MEi4
NK  MmrQRZBweHSxc3nzJGF{e2G7 M3G2dVAvODJvMkCg{txO MW[1JIQ> MYHk[YNz\WG|ZTDOT{Bk\WyuIIDyc4xq\mW{YYTpc44h[W6mII\pZYJqdGm2eTDhd{B1cGViY3;uZ4VvfHKjdHnvckBqdmO{ZXHz[YQ> MVWyN|MzQDB6OB?=
NK  M1K1UGZ2dmO2aX;uJGF{e2G7 M{DSTVAvODFvMkCg{txO MYC1JIQ> M3r5dYNifXOnczDofZBwdWW2aInsZZRqd25ib3[gUmsh[2WubIOgbY4h[SCmb4Pl5qCUemW|cH;ud4U> MW[yN|MzQDB6OB?=
MOLT4/DNR NYDNUZJTTnWwY4Tpc44hSXO|YYm= M2L3NlUh|ryP M1:1OFQh\A>? NEPac|Nz\WS3Y3XzJGFDS0JzIH3SUmEh\XiycnXzd4lwdg>? MkjaNlMxPjB3N{C=
Jurkat/DOX NGLvZ5NHfW6ldHnvckBCe3OjeR?= NGPuc|k2KM7:TR?= MmfnOEBl NX23To9temWmdXPld{BCSkOEMTDtVm5CKGW6cILld5Nqd25? NXz3N2x{OjNyNkC1O|A>
MOLT4/DNR MojXS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NHK2PFQ2KM7:TR?= NVTKN4l4PCCm MkLsdoVlfWOnczD0bIUhUUN3MNMgeoFtfWViZn;yJIRifW6xcoXibYNqdiC|ZX7zbZRqfmm2eR?= MmOxNlMxPjB3N{C=
Jurkat/DOX NI\rN4RIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MoDTOUDPxE1? NX:1bGJ2PCCm M4rsUpJm\HWlZYOgeIhmKEmFNUFCpJZidHWnIH\vdkBl[XWwb4L1ZolkcW5ic3Xud4l1cX[rdIm= NHj6S|YzOzB4MEW3NC=>
ccRCC  M2Ww[mFxd3C2b4Ppd{BCe3OjeR?= MYiwMlAyNTFyzszN MlvvO|IhcA>? Ml3LSG1UVw>? MWfoZZMhdWmwaX3hcEBm\m[nY4Sgc44h[2WubDDwdo9tcW[ncnH0bY9v Mn\iNlI5OjZ2Nke=
TNBC  NHzr[oVCeG:ydH;zbZMhSXO|YYm= MUSwMlAyNTFyzszN Mmn0O|IhcA>? Ml7xSG1UVw>? NWe3SolRcGG|IH3pcolu[WxiZX\m[YN1KG:wIHPlcIwheHKxbHnm[ZJifGmxbh?= MnXnNlI5OjZ2Nke=
A498 NV3vOGczSXCxcITvd4l{KEG|c3H5 NEK3WIYxNjBzLUGw{txO M1zQR|czKGh? NF;PN2ZFVVOR NX;YZm1YcW6mdXPld{B{gW6ncnfpd5Rq[yC{ZYPwc45{\XQEoIfpeIghem:vaXTldJNqdg>? NUK2eJpqOjJ6Mk[0Olc>
KIJ265T M4qzfmFxd3C2b4Ppd{BCe3OjeR?= NYDEZ5FEOC5yMT2xNO69VQ>? MYW3NkBp M2PoU2ROW09? NVvvUoFXcW6mdXPld{B{gW6ncnfpd5Rq[yC{ZYPwc45{\XQEoIfpeIghem:vaXTldJNqdg>? NVruUoMzOjJ6Mk[0Olc>
MDA-231 NInDdY1CeG:ydH;zbZMhSXO|YYm= MVywMlAyNTFyzszN M1;kS|czKGh? MortSG1UVw>? NIGxU45qdmS3Y3XzJJN6dmW{Z3nzeIlkKHKnc4DvcpNme8Lid3n0bEBzd22rZHXwd4lv NVvFZpNzOjJ6Mk[0Olc>
BT-20 MXjBdI9xfG:|aYOgRZN{[Xl? NGjMflExNjBzLUGw{txO MkLvO|IhcA>? MU\EUXNQ MVnpcoR2[2W|IIP5coVz\2m|dHnjJJJme3CxboPld:Khf2m2aDDyc41q\GWyc3nu MVyyNlgzPjR4Nx?=
U937 NEHYeWxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M4PiPFUuOjBizszN NF3rfFMzPC92OD:3NkBp MVrpcoR2[2W|IHGg[IVkemWjc3WgbY4h[2WubDD2bYFjcWyrdImgbY4h[SClb37j[Y51emG2aX;uMUBidmRidHnt[U1l\XCnbnTlcpQhdWGwbnXy MknRNlI4PjdyMkG=
HL60 NWP5SIVGT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MXu1MVIxKM7:TR?= MnHtNlQwPDhxN{KgbC=> NV65WGpEcW6mdXPld{BiKGSnY4LlZZNmKGmwIHPlcIwhfmmjYnnsbZR6KGmwIHGgZ49v[2WwdILheIlwdi1iYX7kJJRqdWVvZHXw[Y5l\W62IH3hco5meg>? NYDIR|ExOjJ5NkewNlE>
U937 NUm2b5VUSXCxcITvd4l{KEG|c3H5 M3PKUlE2KM7:TR?= NFG2d|czPC92OD:3NkBp M2Lzb4lv\HWlZYOgZ4VtdCCjcH;weI9{cXN? M4LFTVIzPzZ5MEKx
HL60 NFe3NVVCeG:ydH;zbZMhSXO|YYm= NI\veosyPSEQvF2= M4DnOVI1NzR6L{eyJIg> NVXZfXl2cW6mdXPld{Bk\WyuIHHwc5B1d3Orcx?= NXTSXpNyOjJ5NkewNlE>
LS411N  MY\BdI9xfG:|aYOgRZN{[Xl? M1\4PFAvPSEQvF2= MUW3NkBp MYrpcoNz\WG|ZYOgSoF{KG2UTlGgcIV3\Wx? NIfi[2czOjR4MU[5OS=>
MDA-MB-231 M4nOfmFxd3C2b4Ppd{BCe3OjeR?= NH7jcGwyOCEQvF2= NEeyeGY1QCCq NVvheXFqemWmdXPld{Bk\WyuII\pZYJqdGm2eTDpckBiKGSxc3Wt[IVx\W6mZX70JI1idm6nch?= NYnBXFU2OjF6OEe2PVc>
MCF-7  M{j3NGFxd3C2b4Ppd{BCe3OjeR?= M2TtVFExKM7:TR?= M{PGS|Q5KGh? MUfy[YR2[2W|IHPlcIwhfmmjYnnsbZR6KGmwIHGg[I9{\S2mZYDlcoRmdnRibXHucoVz MkHxNlE5QDd4OUe=
A375 NX6yUIdTT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NEnhR3QxNjVizszN MXGxM|UwQCCm MXHpcohq[mm2czDwdo9tcW[ncnH0bY9vKGGwZDDpcoR2[2W|IHTp[oZmemWwdHnheIlwdiCxZjDt[Yxidm:vYTDj[Yxtew>? MYCyNVc6PjZ{Mh?=
SKMEL1 Moq4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NFfNS|QxNjVizszN Mnj3NU82NzhiZB?= NGPwPGhqdmirYnn0d{Bxem:uaX\ldoF1cW:wIHHu[EBqdmS3Y3XzJIRq\m[ncnXueIlifGmxbjDv[kBu\Wyjbn;tZUBk\Wyucx?= NEDBWpczOTd7Nk[yNi=>
SKMEL3 NVfi[G8{T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NXXscZlYOC53IN88US=> NUTrWJhJOS93L{ig[C=> NETITpFqdmirYnn0d{Bxem:uaX\ldoF1cW:wIHHu[EBqdmS3Y3XzJIRq\m[ncnXueIlifGmxbjDv[kBu\Wyjbn;tZUBk\Wyucx?= MVyyNVc6PjZ{Mh?=
SKMEL28 NV7QSHhTT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MmrqNE42KM7:TR?= MmDVNU82NzhiZB?= M1rxU4lvcGmkaYTzJJBzd2yrZnXyZZRqd25iYX7kJIlv\HWlZYOg[Iln\mW{ZX70bYF1cW:wIH;mJI1mdGGwb33hJINmdGy| MVKyNVc6PjZ{Mh?=
MeWo MYrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Moj0NE42KM7:TR?= MlHENU82NzhiZB?= NWPwfI1jcW6qaXLpeJMheHKxbHnm[ZJifGmxbjDhcoQhcW6mdXPld{BlcW[oZYLlcpRq[XSrb36gc4YhdWWuYX7vcYEh[2WubIO= NUK3c2pmOjF5OU[2NlI>
B16 NHvhTZRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Ml\zNE42KM7:TR?= MWKxM|UwQCCm MlPCbY5pcWKrdIOgdJJwdGmoZYLheIlwdiCjbnSgbY5lfWOnczDkbYZn\XKnboTpZZRqd25ib3[gcYVt[W6xbXGgZ4VtdHN? NUjuOnhSOjF5OU[2NlI>
Ly 1 MnTCS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NGThbYszPCCq MkjYTWM2OD15LkOg{txO NYr6RnZYOjF5N{KwOFk>
Ly 7 MVrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MXiyOEBp MVPJR|UxRTFyLkeg{txO MX[yNVc4OjB2OR?=
Su-DHL6 NHXPc2VIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3jhblI1KGh? MnG2TWM2OO,:nkKwJO69VQ>? M{nwNFIyPzd{MES5
Ly 10 M3T5dGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NHPmV4IzPCCq MYHJR|Ux97zgMkCg{txO MXSyNVc4OjB2OR?=
RIVA M4XNfmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NUXseXlEOjRiaB?= MnK1TWM2OO,:nkKwJO69VQ>? M1fBSVIyPzd{MES5
Su-DHL2 M1vGTmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MUOyOEBp NXHhXGUyUUN3MP-8olIxKM7:TR?= NELr[mIzOTd5MkC0PS=>
Ly 1 M37TbGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NVSzNocxPDhiaB?= MU\JR|UxRTBwM{Sg{txO MVGyNVc4OjB2OR?=
Ly 7 NXTDWHRuT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M2HZXVQ5KGh? NV[2U5BbUUN3ME2wMlAzPSEQvF2= M2HUcFIyPzd{MES5
Su-DHL6 NI\nV|lIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MUO0PEBp M2r1WGlEPTExvK6yNEDPxE1? NUTGSWY5OjF5N{KwOFk>
Ly 10 MnjaS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MXK0PEBp NXHl[JZMUUN3ME2xMlgh|ryP MlO5NlE4PzJyNEm=
RIVA NFfXToxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NInWR5Y1QCCq NXjKNYdEUUN3MP-8olIxKM7:TR?= Mkm4NlE4PzJyNEm=
Su-DHL2 NWHKbHdKT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NXPtPJlKPDhiaB?= MXfJR|UxRTF5LkSg{txO NF\aXpUzOTd5MkC0PS=>
Ly 1 NH3EeFlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MlHXO|IhcA>? M2TGbWlEPTB;MD6wNUDPxE1? MX:yNVc4OjB2OR?=
Ly 7 NIWxOFdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NI\EXVI4OiCq MXvJR|UxRTBwMEG4JO69VQ>? M3\iN|IyPzd{MES5
Su-DHL6 MnnSS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M2SybVczKGh? NHiyRXZKSzVyPUGuOkDPxE1? MUeyNVc4OjB2OR?=
Ly 10 NHjPV3RIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Ml3JO|IhcA>? MmPSTWM2OD1zLkKg{txO NH7XeWIzOTd5MkC0PS=>
RIVA MmnZS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M{ewVFczKGh? MXTJR|Ux97zgMkCg{txO MYGyNVc4OjB2OR?=
Su-DHL2 NWHS[pN[T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MkCyO|IhcA>? NFPJXJJKSzVyPUGxMlIh|ryP NHzZNJIzOTd5MkC0PS=>

... Click to View More Cell Line Experimental Data

Assay
Methods Test Index PMID
Western blot
Survivin / Bcl-2 / p53 / c-Myc / DNMT1; 

PubMed: 26384351     


HL60/ADR and kasumi-1 cells were lysed after treated with 0, 1, 2, 4μM decitabine for 72h, and antibodies against β-actin was used as loading control of whole cell proteins in western blotting. The expression of DNMT1, c-Myc, P53, Bcl-2 and Survivin were determined in AML cells.

p-AKT / AKT / p-GSK3β / GSK3β / p-Myc / Myc / p-P70 / P70 / p-4EBP-1 / 4EBP-1 / PTEN; 

PubMed: 25762617     


Effects of decitabine on the expression of survival pathway proteins at the indicated concentrations.

phospho-p38 / p38 / phospho-NFκB / NFκB; 

PubMed: 26617834     


Decitabine suppressed the phosphorylation of p38 and NF-κB.

p-JAK1 / JAK1 / p-JAK2 / JAK2 / p-STAT3 / STAT3 ; 

PubMed: 26692933     


DAC inhibits the activity of JAK/STAT3 signaling pathway in HL-60 cells. A. HL-60 cells were exposed to 0.2-1.0 μM DAC for 48 h. Cell lysates were prepared and subjected to western blot assay for p-STAT3 (Tyr705 and Ser727) and total STAT3 protein. DAC treatment led to the dephosphorylation of STAT3 both at Tyr705 and Ser727, with moderate effect on total STAT3 protein. B. DAC also down-regulated the expression of p-JAK1 and p-JAK2 as well as total JAK1 and JAK2 in HL-60 cells. The protein expression of STAT3 and JAKs was normalized to that of β-actin and results are representative from three independent experiments.

E-cadherin / N-cadherin / Snail / MMP-2 / MMP-9 / Bcl-2 / Bax; 

PubMed: 28152502     


The protein level of EMT and invasion related proteins E-cadherin, N-cadherin, Snail, MMP-2, MMP-9 and the protein level of the apoptotic-related proteins, BCL-2 and Bax were detected by western blot. β-actin served as a internal control.

26384351 25762617 26617834 26692933 28152502
Immunofluorescence
DNMT1; 

PubMed: 21303982     


Ren-01 cells (low passage number RCC cells) at <40% confluence were treated with decitabine 0.5 μM. DNMT1 was quantified 48 hours later by immuno-fluorescence (green dots). DAPI was used to stain nuclei (blue stain).

E-cadherin / MMP-9; 

PubMed: 28152502     


Immunofluorescence microscopy to identify invasion-promoting molecule MMP-9 and EMT-protective molecule E-cadherin in YES-2 and TE13 cells treated with DAC. 

21303982 28152502
Growth inhibition assay
Cell viability; 

PubMed: 26384351     


Cells were treated with Decitabine for 72 h. Viability was measured by MTT assay in AML cells and patient samples Different AML cells.

26384351
体内研究 Decitabine 按2.5 mg/kg 剂量作用于ALK+ KARPAS-299小鼠移植瘤模型,促进凋亡,且降低肿瘤细胞增殖,也导致肿瘤抑制基因p16INK4A的去甲基化。 [2]

推荐的实验操作(此推荐来自于公开的文献所以Selleck并不保证其有效性)

激酶实验:[1]
- 合并

DNA合成检测 :

通过测定放射性胸甘摄入到DNA的情况而测定DNA合成比率。HL-60 和KG1a 细胞悬浮在6孔(直径为35 mm )盘中,孔中为含10%胎牛血清的2 mL RPMI 培养基中,然后与不同浓度相应药物温育48小时 (药物同时加入)。48小时时, 每孔加入0.5 μCi [3H] 胸甘(6.7 Ci/mmol),再温育24小时。细胞置于GF/C玻璃纤维过滤器(直径为2.4 cm)中,使用冷 0.9% NaCl, 5% 冷三氯乙酸和乙醇清洗。烘干含DNA的过滤器,置于EcoLite闪烁液(ICN)中,使用 Beckman LS 6000IC 闪烁计数器测量放射性。通过剂量-反应曲线计算IC50值。
细胞实验:[1]
- 合并
  • Cell lines: HL-60 和 KG1a
  • Concentrations: 0 到100 ng/mL
  • Incubation Time: 96 小时
  • Method: 生长抑制实验中,指数生长期细胞接种在5 ml培养基中。向培养基中同时加入不同浓度Decitabine。在指定时间,使用模型 ZM Coulter 计数器对细胞进行计数。根据药物处理的白血病细胞的生长曲线,测定IC50值。
    (Only for Reference)
动物实验:[2]
- 合并
  • Animal Models: KARPAS-299 人类细胞皮下接种到小鼠的左右两侧。
  • Formulation: Decitabine 溶于无菌PBS
  • Dosages: ≤2.5 mg/kg
  • Administration: 腹腔注射
    (Only for Reference)

溶解度 (25°C)

体外 DMSO 45 mg/mL (197.18 mM)
Water 10 mg/mL (43.81 mM)
Ethanol Insoluble
体内 从左到右依次将纯溶剂加入产品,现配现用(数据来自Selleck实验检测而非文献):
water
10mg/mL

* 溶解度检测是由Selleck技术部门检测的,可能会和文献中提供的溶解度有所差异,这是由于生产工艺和批次不同产生的正常现象。请按照顺序依次加入各个纯溶剂。

化学数据

分子量 228.21
化学式

C8H12N4O4

CAS号 2353-33-5
储存条件 粉状
溶于溶剂
别名 Deoxycytidine

计算器

摩尔浓度计算器

摩尔浓度计算器

本计算器可帮助您计算出特定溶液中溶质的质量、溶液浓度和体积之间的关系,公式为:

质量 (mg) = 浓度 (mM) x 体积 (mL) x 分子量 (g/mol)

摩尔浓度计算公式

  • 质量
    浓度
    体积
    分子量

*在配置溶液时,请务必参考Selleck产品标签上、MSDS / COA(可在Selleck的产品页面获得)批次特异的分子量使用本工具。

稀释计算器

稀释计算器

用本工具协助配置特定浓度的溶液,使用的计算公式为:

开始浓度 x 开始体积 = 最终浓度 x 最终体积

稀释公式

稀释公式一般简略地表示为: C1V1 = C2V2 ( 输入 输出 )

  • C1
    V1
    C2
    V2

在配置溶液时,请务必参考Selleck产品标签上、MSDS / COA(可在Selleck的产品页面获得)批次特异的分子量使用本工具。.

连续稀释计算器方程

  • 连续稀释

  • 计算结果

  • C1=C0/X C1: LOG(C1):
    C2=C1/X C2: LOG(C2):
    C3=C2/X C3: LOG(C3):
    C4=C3/X C4: LOG(C4):
    C5=C4/X C5: LOG(C5):
    C6=C5/X C6: LOG(C6):
    C7=C6/X C7: LOG(C7):
    C8=C7/X C8: LOG(C8):
分子量计算器

分子量计算器

通过输入化合物的化学式来计算其分子量:

总分子量:g/mol

注:化学分子式大小写敏感。C10H16N2O2 c10h16n2o2

摩尔浓度计算器

质量 浓度 体积 分子量
计算

临床试验信息

NCT Number Recruitment interventions Conditions Sponsor/Collaborators Start Date Phases
NCT04086238 Recruiting Drug: Decitabine Healthy EpiDestiny Inc. October 9 2019 Phase 1
NCT04113616 Recruiting Drug: KRT-232|Drug: Cytarabine|Drug: Decitabine Acute Myeloid Leukemia (AML)|Acute Myeloid Leukemia (AML) Secondary to Myeloproliferative Neoplasms (MPN) Kartos Therapeutics Inc. September 25 2019 Phase 1|Phase 2
NCT03828084 Completed Drug: Decitabine Healthy EpiDestiny Inc. April 3 2019 Phase 1
NCT03875287 Recruiting Drug: Decitabine|Drug: Cedazuridine Solid Tumor Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins|Astex Pharmaceuticals April 17 2019 Phase 1
NCT03593915 Recruiting Combination Product: Alvocidib Plus Decitabine Myelodysplastic Syndromes (MDS) Tolero Pharmaceuticals Inc. August 29 2018 Phase 1|Phase 2

技术支持

在订购、运输、储存和使用我们的产品的任何阶段,您遇到的任何问题,均可以通过拨打我们的热线电话400-668-6834,或者技术支持邮箱tech@selleck.cn,直接联系到我们。我们会在24小时内尽快联系您。

操作手册

如果有其他问题,请给我们留言。

  • * 必填项

常见问题及建议解决方法

  • 问题 1:

    Is S1200 a racemic mixture or a monomer?

  • 回答:

    S1200 is R form

DNA Methyltransferase Signaling Pathway Map

Tags: 购买Decitabine | Decitabine供应商 | 采购Decitabine | Decitabine价格 | Decitabine生产 | 订购Decitabine | Decitabine代理商
×
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID